The trial is being carried out in 16 nations and regions, including Asia, North America, Europe, and South America.

Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.

Because of the selection of CDK4/6 inhibitors now available in the first-line setting for patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, providers now have the ...

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

Detailed price information for Beyondspring Inc (BYSI-Q) from The Globe and Mail including charting and trades.

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...

NEW HAVEN, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 5, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding ...